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Letters to the Editor
8Reply to: ‘‘Understanding triphasic HCV decline during treatment
in the era of IL28B polymorphisms and direct acting antiviral
agents via mathematical modeling’’Triphasic decline in HCV RNA during peginterferon and
ribavirin therapy for HCV genotype 1
To the Editor:
We thank Dahari et al. for their comments on our recent
manuscript investigating the relationship between IL28B SNP
12979860 and early HCV RNA kinetics in 173 African American
(AA) and 188 Caucasian American (CA) patients infected with
chronic HCV genotype 1, during peginterferon alfa-2a and ribavi-
rin (PegIFN-a-2a/RBV) therapy in the VIRAHEP-C study [1]. Com-
pared to SNP C/T and T/T genotypes, the C/C genotype was
associated with greater phase 1 and faster phase 2 declines in
HCV RNA in both AA and CA patients. Thus, we concluded that
this SNP predicts both interferon (IFN) effectiveness at blocking
HCV production (i.e., phase 1) and clearance of infected hepato-
cytes (i.e., phase 2), and that this could explain how the IL28B
SNP 12979860 C/C genotype increases the probability of SVR
(compared to non-C/C genotypes) following PegIFN-a-2a/RBV
treatment for HCV genotype 1. Differences in early viral kinetics
between AA and CA could be largely explained by racial differ-
ences in the frequency of the IL28B SNP C allele.
Patients with IL28B SNP non-C/C genotypes were more likely
to have either a static phase or an increase in serum HCV RNA
(i.e., shoulder) from day 2–7. We hypothesized that the IL28B
SNP-related variability in the shoulder phase was due primarily
to differences in IFN effectiveness (SNP C/C > C/T and T/T), as
the decline in HCV RNA from day 2–7 was more strongly corre-
lated with the magnitude of phase 1 than the phase 2 slope. In
addition, we noted that the rebound in HCV RNA was temporally
related to the decline in serum peginterferon from day 2/3 to 7
between the ﬁrst and second injection [2]. Furthermore, we cited
evidence that ribavirin also plays a signiﬁcant role in regulating
viral kinetics between day 2–7 [3]. It is known that ribavirin
has no effect on phase 1, either when administered alone or
when combined with peginterferon alfa; when combined with
peginterferon, it prevents an increase (rebound) in HCV RNA
from day 2–7 and accelerates the fall in HCV RNA from day
7–28 (phase 2), in patients with an adequate ﬁrst phase response
[3]. With regard to ribavirin, viral kinetics models that include
ribavirin and IFN effectiveness are better able to explain
early HCV RNA kinetics than models with IFN effectiveness
alone [4]. According to this model, the requirement for ribavirin
during phase 2 is inversely related to IFN effectiveness. Thus,42 Journal of Hepatology 201phase 2 and SVR in patients with IL28B SNP C/C are expected to
be less dependent on ribavirin than in patients with non-C/C
genotypes.
In their letter, Dahari et al. reviewed the prevailing concepts
of the shoulder phase from day 2–7 incorporating observations
from 2 studies of US and Brazilian patients who were co-infected
with HCV and HIV [5,6]. These studies are limited by small sam-
ple sizes and inclusion of patients with HCV genotypes 2 and 3.
Analogous to our study, patients in one study were stratiﬁed by
IL28B SNP genotype [6]. In keeping with our results, HCV geno-
type 1, co-infected patients with SNP C/C genotypes had signiﬁ-
cantly higher ﬁrst (day 0–2) and second (day 2–29) phase
declines in serum HCV RNA [6]. In addition, the peginterferon alfa
serum concentration associated with half maximum IFN effec-
tiveness (EC50) was lower in patients with IL28B SNP C/C geno-
types compared to non-C/C genotypes (p = 0.02), suggesting
that patients with C/C genotype were more sensitive to peginter-
feron. Dahari et al. suggested that the faster declines in serum
HCV RNA from day 2–7 in patients with IL28B SNP C/C in our
study may be partly related to greater IFN sensitivity (peginter-
feron EC50) and a higher infected cell loss rate. Our results are
consistent with the concept that the shoulder phase reﬂects both
IFN effectiveness and the infected cell loss rate. The peginterferon
EC50 (IFN sensitivity) hypothesis is intriguing. However, the dif-
ference in peginterferon EC50 between C/C and non-C/C geno-
types was not signiﬁcant in HIV-co-infected patients with HCV
genotype 1 (p = 0.6), possibly due to inadequate statistical power.
Studies with larger numbers of patients infected with HCV geno-
type 1 alone are needed to address this question and to deter-
mine if peginterferon EC50 is an independent predictor of the
shoulder and second phase responses.
In another study, Dahari et al. observed signiﬁcantly lower
ribavirin plasma concentrations during the ﬁrst 2 weeks and
lower ribavirin exposure or area under the concentration–time
curve (AUC) levels at days 3, 7, 14, and 28 of peginterferon alfa
combination treatment in HCV-HIV co-infected patients who
achieved an SVR relative to those without an SVR [5]. They raised
the possibility that lower early ribavirin levels in patients with
IL28B CC genotypes might explain the transient viral declines
and shoulder phase during the ﬁrst week in our report. In more
recent studies, we have investigated the importance of ribavirin
pharmacokinetics to the lower efﬁcacy of peginterferon and riba-
virin therapy in AA compared to CA with HCV genotype 1 [7,8].3 vol. 58 j 831–843
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The results suggest that ribavirin drug exposure is a key factor
determining HCV RNA dynamics during the shoulder (day 2–7)
in patients with HCV genotype 1 regardless of IL28B SNP geno-
type. We studied 75 AA and 75 CA who were more than 90%
adherent to PegIFN-a-2a and weight-based ribavirin during the
ﬁrst 24 weeks of therapy in the VIRAHEP-C, based on electronic
drug monitoring [7,8]. Compared to CA, AA had lower plasma
ribavirin concentrations at weeks 1, 2, and 4, and lower ribavirin
exposure (AUC) from week 1–12 that were explained by a 50%
higher volume of ribavirin distribution [7,8]. Ribavirin exposure
(AUC) during the ﬁrst week (AUC0–7), IL28B SNP genotype, age,
and platelet count were independent predictors of response
(undetected serum HCV RNA) at week 24 (WK24VR) and week
72 (SVR), in a multivariable regression model [8]. Among AA,
ribavirin AUC0–7 levels were higher in responders at weeks 24
and 72. Ribavirin AUC0–7 cut-offs or thresholds that best distin-
guished WK24VR (P4095 ng/ml d) and SVR (P4480 ng/ml d)
from non-responders were identiﬁed using receiver operating
characteristics curve analysis [8]. Fewer AA (49% and 44%)
achieved the respective AUC0–7 thresholds than did CA (70%
and 64%). In addition, WK24VR and SVR rates were higher in
patients with threshold compared to subthreshold ribavirin
AUC0–7 levels. Yet, there were no differences in WK24VR and
SVR between AA and CA with threshold ribavirin AUC0–7 levels,
providing strong evidence that optimum ribavirin drug exposure
during the ﬁrst week can overcome the racial disparity in
WK24VR and SVR.
It is worth noting that WK24VR and SVR to peginterferon and
ribavirin did not vary by ribavirin exposure category in patients
with the IL28B SNP C/C genotype [8]. In contrast, patients with
IL28B SNP non-C/C and threshold ribavirin AUC0–7 levels had
signiﬁcantly higher WK24VR and SVR rates than those with
subthreshold levels. The importance of ribavirin exposure on
treatment outcomes in this study was reﬂected in the early
HCV RNA kinetics. Compared to CA, AA had a shoulder in serum
HCV RNA from day 2–7 and smaller declines in HCV RNA on days
7, 14, and 28 [8]. The shoulder phase was observed in AA with
subthreshold, but not in those with threshold ribavirin AUC0–7.
HCV RNA kinetics from day 0 to 28 did not differ between AA
and CA with threshold ribavirin AUC0–7. Regardless of IL28B
SNP genotype, patients with subthreshold ribavirin AUC0–7
experienced a shoulder phase from day 2–7. However, phase 2
did not vary by ribavirin AUC0–7 category in patients with IL28B
SNP C/C. In contrast, declines in HCV RNA from day 2–7 and
day 7–28 (phase 2) were greater in non-C/C patients with thresh-
old compared to subthreshold ribavirin AUC0–7 levels. Serum
peginterferon and ribavirin levels did not vary by IL28B SNP geno-
type. These results indicate that suboptimum ribavirin exposureJournal of Hepatology 20was responsible for the shoulder in HCV RNA from day 2–7
during peginterferon combination treatment, and are consistent
with the concept that due to higher IFN effectiveness and infected
cell loss rates, the phase 2 (day 7–28) decline rate is less
dependent on threshold ribavirin exposure in patients with
HCV genotype 1 who carry the IL28B SNP C/C genotype.
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